Hepatitis C therapy: Looking toward interferon-sparing regimens

Journal of the American Pharmacists Association

Volumn 55, Issue 2, 2015, Pages e72-e86

  Au, Trang H ^a   Destache, Christopher J ^b   Vivekanandan, Renuga ^c  

^a UNIVERSITY OF UTAH   (United States)

^b CREIGHTON UNIVERSITY   (United States)

^c CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON;

GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INVESTIGATIVE PROCEDURES; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; MEDLINE; META ANALYSIS; METHODOLOGY; PATHOPHYSIOLOGY; PATIENT RISK; PERSONAL EXPERIENCE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PUBLIC HEALTH PROBLEM; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR; TREATMENT DURATION; TREATMENT RESPONSE; UNITED STATES; ANTIVIRAL RESISTANCE; DRUG COMBINATION; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PATHOGENICITY; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; TREATMENT OUTCOME;

EID: 84924348161     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/JAPhA.2015.15508     Document Type: Review

References (54)

1. Hepatitis C. Fact Sheet No. 164. Geneva, Switzerland: World Health Organization. www.who.int/mediacentre/factsheets/fs164/en/. Accessed July 24, 2014.
2. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144(10):705-714.
3. Recommendations for testing, managing, and treating hepatitis C. American Association for the Study of Liver Diseases and Infectious Diseases Society of America. www.hcvguidelines.org/fullreport. Accessed July 24, 2014.
4. Ly KN, Xing J, Klevens RM, et al. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012;156:271-278.
5. Taylor LE, Swan T, Mayer KH. HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis. 2012;55:S33-S42.
6. Klevens RM, Hu DJ, Jiles R, et al. Evolving epidemiology of hepatitis C virus in the United States. Clin Infect Dis. 2012;55:S3-S9.
7. McCombs J, Matsuda T, Tonnu-Mihara I. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry. JAMA Intern Med. 2014;174:204-212.
8. Salvatierra K, Fareleski S, Forcada A, et al. Hepatitis C virus resistance to new specifically targeted antiviral therapy: a public health perspective. World J Virol. 2013;2:6-15.
9. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399-401.
10. Thompson AJ, Muir AJ, Sulkowski MS, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of sustained virologic response in hepatitis C virus. Gastroenterology. 2010;139:120-9.
11. Davis KL, Mitra D, Medjedovic J, et al. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol. 2011;45:e17-e24.
12. Lin J, Wu J, Zhang Q, et al. Virus-related liver cirrhosis: molecular basis and therapeutic options. World J Gastroenterol. 2014;20(21):6457-6469.
13. Hoggard PG, Owen A. The mechanisms that control intracellular penetration of the HIV protease inhibitors. J Antimicrob Chemother. 2003;51:493-496.
14. Zhu YZ, Qian XJ, Zhao P, et al. How hepatitis C virus invades hepatocytes: the mystery of viral entry. World J Gastroenterol. 2014;20:3457-3467.
15. Selimovic D, El-Khattouti A, Ghozlan H, et al. Hepatitis C virus- related hepatocellular carcinoma: an insight into molecular mechanisms and therapeutic strategies. World J Hepatol. 2012;4:342-355.
16. Andrade LJ, D'Oliveira A, Melo RC, et al. Association between hepatitis C and hepatocellular carcinoma. J Glob Infect Dis. 2009;1:33-37.
17. Hepatitis C FAQs for health professionals. Centers for Disease Control and Prevention. www.cdc.gov/hepatitis/HCV/HCVfaq.htm. Accessed July 31, 2014.
18. Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80-88.
19. Sebastinani G, Castera L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011;34:1202-1216.
20. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection [abstract]. Am J Gastroenterol. 2002;97:2614-2618.
21. Thompson AJ, McHutchison JG. Review article: investigational agents for chronic hepatitis C. Aliment Pharmacol Ther. 2009;29:689-705.
22. Safdar K, Schiff ER. Alcohol and hepatitis C. Semin Liver Dis. 2004;24:305-315.
23. Gitto S, Micco L, Conti F, et al. Alcohol and viral hepatitis: a mini-review. Dig Liver Dis. 2009;41:67-70.
24. Pegasys [product labeling]. Nutley, NJ: Hoffmann-La Roche, Inc.; 2002.
25. Peg-Intron [product labeling]. Kenilworth, NJ: Schering Corp.; 2001.
26. Copegus [product labeling]. South San Francisco, CA: Genentech USA, Inc.; 2011.
27. Rebetol [product labeling]. Whitehouse Station, NJ: Merck & Co, Inc.; 2013.
28. Victrelis [product labeling]. Whitehouse Station, NJ: Merck & Co, Inc.; 2011.
29. Incivek [product labeling]. Cambridge, MA: Vertex Pharmaceuticals, Inc.; 2013.
30. Poordad F, McCone J Jr, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195-1206.
31. Poordad F, Bronowicki JP, Gordon SC, et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology. 2012;143:608-618.e1-e5.
32. Virlogeux V, Pradat P, Bailly F, et al. Boceprevir and telaprevir- based triple therapy for chronic hepatitis C: virological efficacy and impact on kidney function and model for end-stage liver disease score. J Viral Hepat. 2014;2:e98-e107.
33. Macartney MJ, Irish D, Bridge SH, et al. Telaprevir or boceprevir- based therapy for chronic hepatitis C infection: development of resistance-associated variants in treatment failure. Antiviral Res. 2014;105:112-117.
34. Olysio [product labeling]. Titusville, NJ: Janssen Therapeutics, LP; 2013.
35. Kanda T, Nakamoto S, Wu S. New treatments for genotype 1 chronic hepatitis C - focus on simeprevir. Ther Clin Risk Manag. 2014;10:387-394.
36. Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146:1669-1679.e3.
37. Sovaldi [product labeling]. Foster City, CA: Gilead Sciences, Inc.; 2013.
38. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887.
39. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-1877.
40. Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE trial. Washington, DC: 64th Annual Meeting of the American Association for the Study of Liver Diseases; 2013. Abstract 1085.
41. Slomski A. WHO issues guidelines on HCV amid drug cost controversy. JAMA. 2014;311:2262-2263.
42. Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther. 2014;40(6):657-675.
43. Messori A, Maratea D, Fadda V, Trippoli S. Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naïve patients with genotype 1 HCV infection in Italy. Aliment Pharmacol Ther. 2014;40(2):217-218. doi: 10.1111/apt.12823.
44. Fierer DS, Dieterich DT, Fiel MI, et al. Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection. Clin Infect Dis. 2013;56:1038-1043.
45. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014;312:353-361.
46. Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756-1765.
47. FDA approves first combination pill to treat hepatitis C [news release]. Silver Spring, MD: U.S. Food and Drug Administration; October 10, 2014. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm. Accessed November 1, 2014.
48. Harvoni [product labeling]. Foster City, CA: Gilead Sciences, Inc.; 2014.
49. Olysio (simeprevir) gains additional FDA approval as once-daily, all-oral interferon- and ribavirin-free treatment option in combination with sofosbuvir for adults with genotype 1 chronic hepatitis C infection [news release]. November 5, 2014. http://www.jnj.com/news/all/OLYSIO-simeprevir-Gains-Additional-FDA-Approval-as- Once-Daily-All-Oral-Interferon-and-Ribavirin-Free-Treatment-Option-in-Combination-with-Sofosbuvir-for-Adults-with-Genotype-1-Chronic-Hepatitis-C-Infection. Accessed January 25, 2015.
50. Viekira Pak [package insert]. North Chicago, IL: AbbVie Inc.; 2014.
51. AbbVie receives U.S. FDA approval of Viekira Pak (ombitasvir/paritaprevir/ritonavir tablets; dasabuvir tablets) for the treatment of chronic genotype 1 hepatitis C [press release]. December 19, 2014. http://abbvie.mediaroom.com/2014-12-19-AbbVie-Receives-U-S-FDA-Approval-of-VIEKIRA-PAK-Ombitasvir-Paritaprevir-Ritonavir-Tablets- Dasabuvir-Tablets-for-the-Treatment-of-Chronic-Genotype- 1-Hepatitis-C. Accessed January 25, 2015.
52. Vertex to stop selling telaprevir in U.S. by October 2014, but will not stop selling it in Canada [news release]. www.catie.ca/en/news/hepcinfo-updates/2014-08-26. Accessed January 25, 2105.
53. A phase 3 study of a daclatasvir/asunaprevir/BMS-791325 fixed dose combination (FDC) in subjects with chronic hepatitis C genotype 1 (UNITY 4). NCT02170727. https://clinicaltrials.gov/ct2/show/NCT02170727. Accessed January 25, 2015.
54. Grazoprevir (MK-5172) and elbasvir (MK-8742) combination for chronic hepatitis C virus (HCV) genotypes 1, 4, and 6 (MK-5172-065). https://clinicaltrials.gov/ct2/show/NCT02252016. Accessed January 25, 2015.